Xfinity Named Official Internet and Mobile Partner of the Connecticut Sun for the 2025 Season
UNCASVILLE, Conn., May 20, 2025--(BUSINESS WIRE)--The Connecticut Sun announced that Xfinity will serve as the team's Official Internet and Mobile Partner for the 2025 season. The partnership with Xfinity highlights a shared commitment to connectivity, community, and creating meaningful fan experiences throughout New England. Xfinity is Comcast's residential services brand, which offers a full suite of products, including Xfinity Internet, Xfinity Mobile, Xfinity X1 and Xfinity Home Solutions.
"Xfinity's partnership with the Connecticut Sun is a new opportunity to make a significant impact in our community by supporting local events and helping young people become the next generation of leaders, business owners, and athletes," said Jessica Muir, Senior Director, Brand Partnerships and Engagement at Comcast. "By becoming the Connecticut Sun's official Internet and Mobile Partner, we'll be able to bring fans closer to what they love."
As part of their partnership, Xfinity and the Connecticut Sun will activate a number of engaging initiatives both on and off the court, reinforcing the power of connection in sports and beyond. Xfinity will serve as the presenting sponsor of the official Connecticut Sun podcast, Keep Shinin', as well as the Connecticut Sun mobile app, helping enhance the digital experience for fans throughout the season.
"We're thrilled to welcome Xfinity to the Connecticut Sun family," said Jen Rizzotti, President of Connecticut Sun. "This partnership goes beyond the game—it's about bringing people together, celebrating our community, expanding access to technology, and increasing awareness and visibility to the incredible things our athletes are doing on and off the court."
Xfinity will also be the presenting sponsor of the Connecticut Sun's "Where to Watch" graphics on social media, helping fans stay connected to every game, home and away. A four-part social content series—featuring players, coaches, and the team's mascot Blaze in a lighthearted and entertaining format—will be rolled out throughout the season.
In the arena, Xfinity will surprise fans with exclusive seat upgrade experiences, bringing fans courtside at Sun home games. Additionally, a special Xfinity-branded giveaway item will be distributed to the first 2,500 fans during the Sun's game against the Minnesota Lynx on August 30 at 7:00 PM EST, further enhancing the in-game experience.
Demonstrating a shared commitment to community, Xfinity and the Connecticut Sun will also present three events throughout the season, including a community-based event and two "Basketball for Free" clinics.
About Comcast Corporation
Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information.
About Connecticut Sun
Established in 2003, the Connecticut Sun is a professional women's basketball team in the Women's National Basketball Association that takes residence at Mohegan Sun Arena in Uncasville, CT. For more information or to purchase season tickets, visit www.connecticutsun.com or call 1-877-SUN-TIXX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520918445/en/
Contacts
Media:
Connecticut Sun Alexandra Maund(860) 705-9649amaund@connecticutsun.com
Caroline O'Keefe(860) 823-7561cokeefe@connecticutsun.com
Xfinity Kristen Roberts860-982-9740kristen_roberts@comcast.com
Elizabeth Walden860-918-3545elizabeth_Walden@comcast.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength
Honeywell International Inc. (NASDAQ:HON) is one of the best Dow stocks to invest in. On June 9, the company announced that it had finalized its $2.16 billion all-cash acquisition of Sundyne from private equity firm Warburg Pincus. Sundyne, known for its advanced pumps and gas compressors used in process industries, is expected to contribute immediately to Honeywell International Inc. (NASDAQ:HON)'s revenue growth, segment margins, and adjusted earnings per share during the first full year of ownership. Sundyne brings strong customer relationships and top-tier technology, which are expected to enhance Honeywell UOP's presence in areas like refining, petrochemicals, LNG, and clean energy. Integrated with the Honeywell Forge platform, the combined offering strengthens Honeywell's position in the energy transition by providing a comprehensive, scalable solution. This acquisition comes on the heels of Honeywell International Inc. (NASDAQ:HON)'s recent announcement to spin off its Aerospace Technologies and Solstice Advanced Materials units, moves aimed at creating three separate publicly traded companies, each with focused strategies and growth opportunities. Since December 2023, Honeywell has pursued several strategic initiatives to boost organic growth and streamline its operations, including $13.5 billion in value-enhancing acquisitions. The company operates globally across a wide range of industries. HON has surged by over 7% in the past 12 months. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
How major US stock indexes fared Wednesday, 6/11/2025
Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China. On Wednesday: The S&P 500 fell 16.57 points, or 0.3%, to 6,022.24. The Dow Jones Industrial Average fell 1.10 points, or less than 0.1%, to 42,865.77. The Nasdaq composite fell 99.11 points, or 0.5%, to 19,615.88. The Russell 2000 index of smaller companies fell 8.17 points, or 0.4%, to 2,148.23. For the week: The S&P 500 is up 21.88 points, or 0.4%. The Dow is up 102.90 points, or 0.2%. The Nasdaq is up 85.92 points, or 0.4%. The Russell 2000 is up 15.99 points, or 0.7%. For the year: The S&P 500 is up 140.61 points, or 2.4%. The Dow is up 321.55 points, or 0.8%. The Nasdaq is up 305.08 points, or 1.6%. The Russell 2000 is down 81.92 points, or 3.7%. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
38 minutes ago
- Yahoo
Allarity Therapeutics Announces Changes to Board of Directors
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
